Neuronetics (STIM) Q4 2025: Greenbrook Clinics Drive 28% Pro Forma Revenue Growth, Setting Stage for New Therapies

2026-03-17 | By EarningsIQ Research

Neuronetics delivered a pivotal quarter, with Greenbrook clinics powering double-digit pro forma growth and operational cash flow turning positive for the first time. The company’s vertically integrated mental health model is gaining traction, as new referral channels and digital tools accelerate patient access and treatment conversion. Looking ahead, the Compass Pathways partnership and further expansion in treatment-resistant depression therapies position Neuronetics for continued evolution, though reimbursement and integration execution remain key watchpoints.

Summary

• Clinic Network Momentum: Greenbrook’s double-digit growth and referral expansion are transforming Neuronetics’ revenue mix and reach.
• Operational Leverage Emerging: Positive operating cash flow and margin discipline signal improved cost structure despite lower-margin clinic business mix.
• Therapy Pipeline Catalyst: Upcoming Compass Pathways launch could unlock a new growth vector in treatment-resistant depression.

Performance Analysis

Neuronetics’ Q4 2025 results reveal a business in transition, with the Greenbrook acquisition now fully embedded and reshaping both revenue and operational dynamics. Adjusted pro forma revenue grew 23% year-over-year, led by a 28% surge in Greenbrook clinic revenue, which now anchors the company’s top line. The Neurostar segment, encompassing both system sales and treatment sessions, delivered steady 9% pro forma growth, with capital shipments and average selling prices both exceeding internal targets.

Gross margin compressed to 52% from 66% a year ago, reflecting the expanded clinic footprint’s lower inherent margin, but Q4 marked the highest margin quarter of the year due to efficiency measures and favorable product mix. Operating expenses grew modestly—just 1.4%—despite the much larger business, underscoring ongoing discipline. Most notably, Neuronetics achieved positive operating cash flow for the first time, a milestone resulting from improved revenue cycle management and cost controls. The company ended the year with $34.1 million in cash, even after a $5 million debt paydown to reduce interest expense.

• Clinic Revenue Acceleration: Greenbrook clinics now contribute the majority of revenue, with patient referrals and treatment sessions up sharply.
• Neurostar System Resilience: Strong Q4 shipments and ASPs reflect effective targeting of TMS-ready accounts and stable demand.
• Margin Trade-Offs: Lower clinic gross margins are partially offset by operational efficiencies and higher system ASPs.

While the business is more diversified and capital efficient, the shift to a clinic-heavy model brings lower margins and greater operational complexity, requiring ongoing execution to sustain profitability improvements.

Executive Commentary

Strategic Positioning

1. Vertically Integrated Mental Health Platform

Neuronetics’ business model now combines proprietary technology (Neurostar TMS, transcranial magnetic stimulation device) with a national clinic footprint (Greenbrook), allowing the company to control both product and care delivery. This integration enables rapid rollout of new therapies, direct patient engagement, and greater capture of clinical economics—at the cost of lower blended margins and increased operational complexity.

2. Referral and Conversion Engine

Field engagement, digital tools, and educational outreach are driving a 46% increase in patient referrals and a 25% rise in new referring providers, expanding the funnel for both TMS and Spravato (esketamine therapy for depression). Automated intake, AI-enabled benefits investigation, and QR code scheduling are improving conversion rates and cash collections, enhancing the scalability of the clinic model.

3. New Therapy Launchpad

With the Compass Pathways collaboration, Neuronetics is positioning Greenbrook as the go-to clinical network for next-generation mental health treatments, starting with COMP360 psilocybin for treatment-resistant depression. The company’s REMS-compliant (Risk Evaluation and Mitigation Strategy, a regulatory framework for high-risk drugs) infrastructure, built for Spravato, is a competitive advantage for rapid adoption of new modalities.

4. Capital Allocation and Balance Sheet Discipline

Debt paydown and expense control have improved financial flexibility, while targeted capital deployment—such as expanding the Neurostar sales team and investing in efficiency initiatives—supports both growth and profitability goals.

5. Market Access and Reimbursement Savvy

Neuronetics’ experience navigating buy-and-bill versus administer-and-observe models for Spravato, and its proactive stance on payer coverage for new therapies, are critical for ensuring new treatments are both accessible and profitable.

Key Considerations

This quarter marks a strategic inflection for Neuronetics, as it transitions from a device-centric to a platform-driven mental health company. Investors should weigh the following:

Key Considerations:

• Clinic Model Scale-Up: Greenbrook’s rapid growth is driving top-line gains but requires ongoing margin management and operational execution.
• Therapy Diversification: Expansion into Spravato and upcoming COMP360 therapies broadens the addressable market but introduces regulatory and reimbursement complexity.
• Cash Flow Sustainability: Positive Q4 operating cash flow is encouraging, but seasonal and investment-driven volatility will persist, especially in the first half of 2026.
• Leadership Transition: Incoming CEO Dan Revers brings deep medtech experience, but execution continuity during the leadership handoff will be closely watched.

Risks

Integration risk remains high as Neuronetics continues to absorb Greenbrook and scales new therapies across its network. Clinic gross margins are structurally lower than legacy device sales, requiring sustained efficiency gains to protect profitability. Regulatory and reimbursement uncertainties around emerging therapies, such as COMP360, could delay or dampen expected growth. Ongoing legal investigations related to Greenbrook’s pre-acquisition billing practices introduce additional headline and financial risk.

Forward Outlook

For Q1 2026, Neuronetics guided to:

• Total revenue of $33 to $35 million, reflecting typical seasonal softness in both clinic and device segments

For full-year 2026, management guided to:

• Total revenue of $160 to $166 million (midpoint: >9% YoY growth)
• Clinic revenue growth in the double digits to mid-teens
• Neurostar business growth in the low to mid-single digits
• Gross margin of 47% to 49%
• Operating expenses of $100 to $105 million, with run-rate below $100 million by Q4
• Operating cash flow negative $13 to $17 million, with cash flow turning positive in the second half

Management emphasized:

• Seasonality and investment in efficiency initiatives will weigh on H1, but margin and cash flow improvements are expected in H2
• COMP360 launch preparations and payer engagement are underway, with limited incremental investment needed due to existing REMS infrastructure

Takeaways

Neuronetics is now a scaled, vertically integrated mental health platform—but the shift brings new operational and margin realities.

• Clinic-Driven Growth: Greenbrook’s expansion is the key revenue lever, but requires vigilance on margin and execution as therapy mix evolves.
• Therapy Pipeline Optionality: The Compass Pathways partnership positions Neuronetics to capture future growth in treatment-resistant depression and potentially other mental health conditions.
• Cash Flow and Margin Watch: Investors should monitor the sustainability of operating cash flow and the pace of margin stabilization as the business model matures.

Conclusion

Neuronetics’ Q4 results confirm the Greenbrook integration is driving scale and top-line momentum, with operational discipline yielding the company’s first positive operating cash flow. The evolving therapy mix and upcoming pipeline catalysts offer significant upside, but success will depend on execution, payer adoption, and navigating the complexities of a lower-margin, clinic-centric business.

Industry Read-Through

Neuronetics’ performance underscores a broader industry shift toward vertically integrated care models in mental health, where device makers increasingly own the patient journey and capture downstream economics. The rapid adoption of digital intake, AI-enabled claims, and REMS-compliant infrastructure signals that operational sophistication is now table stakes for scaling novel therapies. Competitors in neuromodulation, psychiatric care, and specialty pharma should note the growing importance of payer engagement, referral network development, and therapy launch playbooks as barriers to entry. As psychedelic and other next-gen treatments near commercialization, the ability to seamlessly integrate new modalities into existing clinic networks will be a key differentiator.

STIM Healthcare Mental health Clinic network Therapy launch Integration Cash flow Reimbursement